Needham Maintains Buy on Immuneering, Raises Price Target to $18
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Needham analyst Ami Fadia maintains Immuneering (NASDAQ:IMRX) with a Buy and raises the price target from $11 to $18.
Needham analyst Ami Fadia maintains Immuneering (NASDAQ:IMRX) with a Buy and raises the price target from $11 to $18.